^
    12h
    ROTOR: Epidemiology and Treatment of HR+/HER2- Breast Cancer in England (clinicaltrials.gov)
    P=N/A, N=218677, Completed, Novartis Pharmaceuticals
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    14h
    BRIA-ABC: Combination Study of SV-BR-1-GM With Retifanlimab (clinicaltrials.gov)
    P1/2, N=36, Completed, BriaCell Therapeutics Corporation | Enrolling by invitation --> Completed | Trial completion date: Nov 2028 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    15h
    AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Shengjing Hospital
    New trial
    |
    HR positive
    15h
    An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    16h
    GIM531-CT01: Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=117, Recruiting, Georgiamune Inc | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    17h
    STU-2021-1043: Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, University of Texas Southwestern Medical Center | N=80 --> 51 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    19h
    A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (clinicaltrials.gov)
    P3, N=912, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Dec 2026 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    fulvestrant • AiRuiKang (dalpiciclib)
    19h
    Well-Being After Breast Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=316, Completed, Duke University | Active, not recruiting --> Completed
    Trial completion
    20h
    A Study of the Use of Text Message Reminders to Take Palbociclib (clinicaltrials.gov)
    P=N/A, N=45, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Ibrance (palbociclib)
    20h
    CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)
    P3, N=258, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • Truqap (capivasertib)
    21h
    Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, Istituto Oncologico Veneto IRCCS | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    22h
    SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial (clinicaltrials.gov)
    P2, N=90, Recruiting, Mayo Clinic | N=69 --> 90
    Enrollment change